IDL Biotech: Q2 review

Research Note

2019-08-22

09:09

IDL reports sales in line, but a lower negative EBIT than expected. We provide you with a short review of the report.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.